Clarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Reuters

2025/07/17

<a href="https://laohu8.com/S/CU6.AU">Clarity Pharmaceuticals</a> Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Clarity Pharmaceuticals Ltd., a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen $(PSA)$ levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN32266) on July 17, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2552548128"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552548128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552548128?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552548128","market":"nz","top_or_hot":-1,"title":"Clarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a>, a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen <a href=\"https://laohu8.com/S/PSA\">$(PSA)$</a> levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN32266) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-17 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a>, a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen <a href=\"https://laohu8.com/S/PSA\">$(PSA)$</a> levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN32266) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CU6.AU","symbol_name":"CLARITY PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL1K2nwT:1","article_id":"2552548128","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552548128","pubTimestamp":1752757319,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire  on July 17, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CU6.AU":"CLARITY PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Clarity Pharmaceuticals完成Co-PSMA试验的招募，评估64Cu-SAR-bisPSMA在前列腺癌成像中的应用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":0.9},"content_text":"Clarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging\n    \n\nClarity Pharmaceuticals Ltd., a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen $(PSA)$ levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN32266) on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}